Approaches in Newly Diagnosed Multiple Myeloma: When and What

Program Goals

Case 1

Diagnostic Criteria Multiple Myeloma Requiring Therapy

IMWG Cytogenetic Risk Features

Components of Myeloma Therapy Transplant Eligible Patients

Role of Early ASCT in MM

ASCT in MM Today By the Numbers

IFM 2013-04 VTD vs Bortezomib, Cyclophosphamide, Dex

Role of MRD Testing in MM

MRD Assessment

IFM 2009 Study

MM Biology and Treatment Race/Ethnicity

EMN02/HO95 VMP vs Single ASCT or Double ASCT

STaMINA Trial BMT CTN 0702

Allogeneic SCT

Monitoring

Key Takeaways Newly Diagnosed Transplant Eligible

Case 2

Smoldering Myeloma 2014 IMWG Criteria

Case 2 (cont) 4 years later

Selecting Therapy

SWOG S0777 VRD vs Rd

FIRST Trial Continuous Rd vs Rd-18 vs MPT

Components of Myeloma Therapy Transplant Ineligible Patients

FIRST Trial Continuous and Fixed-Cycle RD

Monitoring

Future Directions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)